CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy
The trial is designed as a phase II evaluation of the effect of CY-503 on progression free survival (PFS) in patients with stage IV malignant melanoma after failure of prior therapy. The aim of the study is at least a rate of 25% (PFS \>/= 3 months).
Melanoma
DRUG: CY-503
Tumor assessment by CT and MRT, each 8 weeks
Immunological response (e.g. measurement of cytokines in serum), each 4 weeks|Assessment of quality of life using a standardized questionnaire, each 4 weeks
The trial is designed as a phase II evaluation of the effect of CY-503 on progression free survival (PFS) in patients with stage IV malignant melanoma after failure of prior therapy. The aim of the study is at least a rate of 25% (PFS \>/= 3 months).